High ADAM17 expression was related to tumor invasiveness or adverse prognosis also in hepatocellular carcinoma [51], breast cancer [52], clear-cell renal carcinoma [53] and glioblastoma [54]. This evidence concerns the gene ADAM17 and hepatocellular carcinoma.